🔗 Share this article

A shadow market for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Investigational Treatment Gaining Traction Via Social Media

The experimental drug, which is still in clinical trials, is being promoted by online personalities for its supposed fat-burning effects. Followers are encouraged to contact these profiles privately for source information, while also receiving discount codes.

Active Commerce on Messaging Platforms

Additionally, a robust market exists on messaging services, where groups with numerous of participants share comparison photos, administration instructions and claims of next-day UK delivery. Sellers promote the substance there before directing buyers to other platforms for purchases.

Learning About Retatrutide

This medication is an investigational injection created by US drugmaker Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could help individuals reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the successor to Ozempic.

Medical Professionals Voice Worries

Nevertheless, physicians and pharmacists have cautions that the distribution of what remains an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals administering substances of uncertain source.

Several professionals said the demand for retatrutide could be connected to the increasing cost of licensed weight loss products such as Mounjaro.

Regulatory Position and Implementation

Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved medication that must not be marketed or distributed for personal consumption under the British medical regulations.

Some influencers try to sidestep the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but advertising and supply can still violate medicines, marketing, and consumer regulations, risking fines, prosecution or imprisonment.

Platform Reaction and Content Elimination

According to TikTok, the platform has removed problematic content and prohibited associated hashtags and query recommendations. The company said it was dedicated to maintaining the service secure and investing in enhancing enforcement strategies.

Online Trading Operations

Investigations also found groups with up to nine thousand participants selling retatrutide using Telegram's built-in discovery tool, which functions like a public directory. Entering “retatrutide” instantly displays channels with thousands of members, populated with photos of weight loss, glowing testimonials and step-by-step instructions for preparing or injecting at residence.

Within moments of entering one group, a seller posted contact information, where the majority of purchases occur. The seller sent an instruction manual and promised shipping within two days. When questioned whether the product was genuine, one seller responded: “You can’t be sure.” Another shared a image of a supposed testing documentation. None inquired about weight, medical conditions or previous experience.

Product Details and Pricing

Inside these groups, messages show black plastic packages with postal service stickers, stating to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, prepared at residence with purified liquid, or ready-to-use pens typically priced at £160 for 20mg. When asked how long a injector should be used, vendors give conflicting answers varying between a few weeks to “depends on your body”.

Platform Oversight and Safety Measures

A representative for the messaging service said it actively moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are injecting substances they can’t verify. Although the research behind retatrutide is valid, these online products may not contain what they advertise,” said Jason Murphy, the head of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to recent cost increases for authorized slimming drugs such as Mounjaro. “With prices rising, patients are using online platforms. But counterfeit treatments are extremely risky. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she explained.

Her team has already encountered individuals harmed by personal administration from unverified sources. “We recognize the frustration, but buying from Telegram or communication platforms is gambling with your well-being,” said Wyllie. “These substances could be impure or improperly measured.”

Manufacturer Position

A spokesperson from Eli Lilly stated the substance was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency globally. “Therefore at this time no one can market [it] for human use,” they said, noting that any product “misleadingly claiming itself as a Lilly investigational product not yet approved … may expose patients to possibly serious medical dangers”.